REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, August 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress. Conference Call and Webcast Information: Dial-in: (800) 715-9871 (U.S. toll free) or (646) 307-1963; conference ID 6539267.Live webcast with slides can be accessed at: https://ir.revmed.com/events-and-presentations. A replay of the webcast will be available on the company’s website shortly after the conference call concludes at https://ir.revmed.com/events-and-presentations and will be archived there for at least 14 days. About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are in clinical development. Additional RAS(ON) Inhibitors in development include RMC-9805 (KRASG12D) and RMC-8839 (KRASG13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1). Contact Information David S. ArringtonSVP Investor Relations & Corporate AffairsRevolution Medicines650-452-6046darrington@revmed.com